Investment analysts at Piper Sandler initiated coverage on shares of Upstream Bio (NASDAQ:UPB - Get Free Report) in a research report issued to clients and investors on Tuesday, Briefing.com reports. The brokerage set an "overweight" rating and a $75.00 price target on the stock. Piper Sandler's price objective would indicate a potential upside of 198.21% from the company's current price.
A number of other research firms have also recently issued reports on UPB. William Blair assumed coverage on Upstream Bio in a research report on Tuesday. They set an "outperform" rating on the stock. JPMorgan Chase & Co. started coverage on Upstream Bio in a research report on Tuesday. They set an "overweight" rating and a $38.00 target price for the company. Finally, TD Cowen initiated coverage on Upstream Bio in a report on Tuesday. They set a "buy" rating for the company.
Get Our Latest Stock Report on UPB
Shares of UPB opened at $25.15 on Tuesday. Upstream Bio has a 52 week low of $20.74 and a 52 week high of $27.68.
In related news, Director Erez Chimovits bought 825,000 shares of the company's stock in a transaction on Tuesday, October 15th. The stock was bought at an average cost of $17.00 per share, with a total value of $14,025,000.00. Following the completion of the purchase, the director now owns 4,554,873 shares in the company, valued at approximately $77,432,841. The trade was a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, Director Erez Chimovits acquired 825,000 shares of the stock in a transaction that occurred on Tuesday, October 15th. The stock was purchased at an average cost of $17.00 per share, for a total transaction of $14,025,000.00. Following the completion of the transaction, the director now directly owns 4,554,873 shares in the company, valued at $77,432,841. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Ai Upstream Llc bought 1,175,000 shares of the firm's stock in a transaction dated Tuesday, October 15th. The shares were bought at an average price of $17.00 per share, with a total value of $19,975,000.00. Following the completion of the transaction, the insider now directly owns 1,175,000 shares in the company, valued at approximately $19,975,000. The disclosure for this purchase can be found here.
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.